+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Drugs of Abuse POC/Decentralized Testing Market, 2019-2023: Supplier Shares and Strategies, Sales Forecasts, Emerging Technologies, Instrumentation Review-Physician Offices, Emergency Rooms, Ambulatory Care Centers

  • PDF Icon

    Report

  • 165 Pages
  • May 2019
  • Region: United States
  • VPG Market Research
  • ID: 4173328
This new 165-page report from the author contains 14 tables, and provides a comprehensive analysis of the POC drugs of abuse testing market, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effective business, R&D and marketing strategies for the global POC abused drugs market.

Rationale
The growing economic pressures on hospitals, coupled with advances in diagnostic technologies, intensifying competition among suppliers and physicians, and changing consumer demands are shifting diagnostic testing from hospitals and commercial laboratories closer to the patient.

Market Segmentation Analysis
  • Review of three POC market segments, including their dynamics, trends, structure, size, growth and major suppliers.



Five-year test volume and reagent sales forecasts for drugs of abuse procedures by market segment:
  • Physician Offices/Group Practices

  • Emergency Rooms

  • Ambulatory Care Centers

  • Analysis of drugs of abuse procedures



Competitive Assessments
  • Assessments of major POC suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, joint ventures, and new products in R&D.



Strategic Recommendations
  • Specific opportunities for new instruments and reagent systems with potentially significant market appeal during the next five years.

  • Design criteria for POC testing products.

  • Alternative business expansion strategies.

  • Potential market entry barriers and risks.



Methodology
This report is based on a combination of primary and secondary sources of information, including review of the latest technical and business publications, manufacturer product literature, industry analyst reports, and the author's proprietary data files.

Companies Mentioned

  • Abbott Laboratories

  • Agilent Technologies

  • Beckman Coulter/Danaher

  • bioMerieux

  • Bio-Rad

  • DiaSorin

  • Eiken Chemical

  • Fujirebio

  • Grifols

  • Instrumentation Laboratory/Werfen

  • Kyowa Medex

  • Ortho-Clinical Diagnostics

  • PerkinElmer

  • Quest Diagnostics

  • Roche

  • Siemens Healthineers

  • Sysmex

  • Thermo Fisher

  • Tosoh

  • Wako